EMA PBRER Guide: Common Mistakes to Avoid at Review Time

The Periodic Benefit-Risk Evaluation Report is the most complex routine pharmacovigilance document a marketing authorization holder must produce. Unlike expedited reports or signal assessments, the PBRER requires synthesizing data from clinical trials, spontaneous reporting systems, published literature, post-market studies, and epidemiological sources into a coherent benefit-risk narrative across a defined reporting interval. The EMA reviews PBRERs submitted as Periodic Safety Update Reports (PSURs) under EU pharmaceutical legislation, and these assessments can trigger variations, label changes, or withdrawal procedures.

Despite the stakes, certain sections of the PBRER are consistently written poorly across the industry. This blog identifies those sections, explains what reviewers expect, and offers concrete guidance on how to meet that bar. The focus is on EMA review, though the principles apply to FDA, Health Canada, and ICH member regulators broadly.

Periodic Benefit-Risk Evaluation Report (PBRER) Framework

The PBRER is described in ICH E2C(R2), which replaced the older PSUR format. The report is built around a defined international birth date (IBD) and a data lock point (DLP), and covers a reporting interval that may be 6 months, 12 months, or longer, depending on product maturity and regulatory requirements. In the EU, the PSUR/PBRER must be submitted within 70 calendar days of the DLP for reports covering 6 or 12 months, and within 90 days for longer intervals.

The primary objective is not safety data collection. It is a benefit-risk evaluation. A PBRER that reads as a safety adverse event catalogue without genuine integration of efficacy and effectiveness data misses the point of the report and will generate questions from EMA reviewers. The CHMP’s PSUR Assessment Reports routinely note this failure.

Section 6: Actions Taken for Safety Reasons - The Most Overlooked Section

Section 6 must document all actions taken during the reporting interval for safety reasons, by the MAH or by regulatory authorities. This includes label changes, Dear Healthcare Professional letters, risk minimization measure updates, volume-adjusted withdrawal of lots, and any marketing authorization suspensions or withdrawals in any country.

Many teams treat Section 6 as an administrative checkbox. It is not. EMA reviewers use this section to understand whether the MAH is proactively managing its risk profile or reacting passively to signals. A section that lists actions without context, without explaining the signal that triggered the action, and without indicating the outcome of the intervention, fails the purpose of the section. Each action should be connected to the underlying safety concern and cross-referenced to the signal evaluation section of the report.

Section 16: Signal and Risk Evaluation - Where the Most Errors Occur

Section 16 is the signal evaluation section. It must describe all signals identified, evaluated, or closed during the reporting interval. This includes signals from spontaneous reports, published literature, clinical trials, post-marketing studies, and data from competent authorities.

The most common errors in Section 16 are using disproportionality statistics such as PRR or ROR as the sole basis for signal characterization, failing to include a clinical evaluation of plausibility alongside the quantitative signal detection output, presenting closed signals without documenting the evidence reviewed and the conclusion reached, and omitting signals that were evaluated informally but not through a formal signal management process.

EMA reviewers expect Section 16 to demonstrate a systematic signal detection methodology, not ad hoc review. The section should describe the data sources monitored, the detection methodology used, and for each signal, the evidence reviewed, the assessment of causality and clinical significance, and the MAH’s conclusion. Recommendations for label changes or further investigation must be clearly stated.

Section 17: Evaluation of Benefit and Risk - The Defining Section

Section 17 is the benefit-risk evaluation. This is where most teams invest insufficient effort. The section must present the integrated benefit-risk profile of the medicinal product, considering the benefit in approved indications alongside the risks identified. It must be structured around a decision context that defines the patient population, the condition being treated, the comparators, and the treatment goals.

The benefit-risk assessment is not a conclusion appended to a safety narrative. It is an analytical exercise that must identify the key benefits, quantify them where possible, identify the key risks, quantify them where possible, and then assess whether the benefit-risk balance remains positive across the approved uses. If there are specific subpopulations where the balance is different, this must be addressed explicitly.

Many teams write Section 17 as a brief summary of Section 16 followed by a conclusion that the benefit-risk profile is positive. EMA assessors have repeatedly noted this deficiency. The expectation is a structured benefit-risk analysis, not a statement. If structured frameworks such as the PrOACT-URL framework or the IMI PROTECT frameworks have been used, the methodology should be briefly described. Consistency between Section 17 and the Reference Safety Information in the Annex is mandatory.

Section 7: Worldwide Marketing Authorization Status - Frequently Incomplete

Section 7 must document the worldwide regulatory status of the product across all countries where it holds a marketing authorization, is under review, or has been refused, suspended, or withdrawn. Many MAHs with large global portfolios maintain incomplete or outdated worldwide authorization databases, and this shows in Section 7.

Reviewers use Section 7 to identify regulatory actions taken in other jurisdictions that may not yet be reflected in the EU label. If a product has been withdrawn from the US market for safety reasons during the reporting interval, that must appear in Section 7, even if the withdrawal is still under appeal. Omissions here create serious credibility issues for the entire report.

Section 15: Overall Safety Evaluation - Avoid the Data Recycling Trap

Section 15 is the overall safety evaluation and must present a cumulative analysis of the safety profile across all sources. The error made most frequently here is repeating the content of Section 14, which covers the analysis of safety data from the reporting interval, without adding the cumulative perspective.

The cumulative view requires comparison of the current reporting interval data against prior intervals. Has the frequency of any adverse event changed? Has a previously rare event become more common as exposure increases? Has a signal that was under evaluation been resolved or escalated? These comparisons must be made explicitly, with reference to prior PBRERs where relevant.

Practical Recommendations for PBRER Authors

Never treat Section 17 as a summary paragraph. Commit to structured benefit-risk analysis with explicit consideration of clinical context, quantified benefits and risks, and acknowledgment of uncertainties.
Build a formal signal management tracker that documents each signal’s status, data sources reviewed, clinical evaluation, and outcome. Use this tracker as the primary input to Section 16.
Audit Section 6 entries for completeness by cross-checking the worldwide regulatory status database, safety variation procedures, and DHPC records from the reporting interval.
Ensure Section 7 is built from a live global authorization database, updated at least quarterly, and reviewed immediately before the DLP.
Write Section 15 with explicit cumulative comparisons. Include tables that compare adverse event frequencies from prior intervals to the current interval and explain material differences.

Conclusion

The PBRER is not a regulatory obligation to minimize. It is the primary mechanism through which an MAH demonstrates ongoing vigilance, scientific rigor, and accountability for its products after approval. EMA reviewers read PBRERs as a window into the quality of a company pharmacovigilance system. The sections described in this blog are the ones that reveal the difference between teams that understand that purpose and those that do not.